Background:The role of surgery in the treatment of non–small-cell lung cancer (NSCLC) with clinically manifested mediastinal node metastasis is controversial even in resectable cases because it is often accompanied by systemic micrometastasis. However, surgery is occasionally indicated for cases with single-station N2 disease or within multimodal treatment regimens, and in clinical trials. The aim of this study is to evaluate surgical outcomes in a modern cohort of patients with clinical (c-) stage IIIA-N2 NSCLC whose nodal metastasis was confirmed by pathology (cN2/pN2).Methods:From the central database of lung cancer patients undergoing surgery in 2004, which was founded by the Japanese Joint Committee for Lung Cancer Registration, data o...
PurposeTo investigate prognoses of lung cancer patients prospectively enrolled in the Japan Lung Can...
OBJECTIVES: Treatment patterns and outcomes in a population-based database were examined to identify...
ObjectiveOptimal management of stage IIIA-N2 non–small cell lung cancer remains controversial. The s...
Background:The role of surgery in the treatment of non–small-cell lung cancer (NSCLC) with clinicall...
AbstractObjectivesNon–small cell lung cancer with mediastinal lymph node involvement is a heterogene...
Background: Surgery has been considered the most effective and standard treatment modality in non-sm...
OBJECTIVE: The surgical treatment of residual N2 disease following induction radio-chemotherapy (IT...
Objective: The role of surgery in patients with N2 non–small cell lung cancer is debated. The aim of...
ObjectiveThe aim of the present study was to identify the modern surgical results of pathologic T3 l...
To investigate the survival and prognostic factors in patients undergoing potentially curative resec...
Background:In the current TNM staging system revised in 1997 for lung cancer, intrapulmonary metasta...
To clarify the prognostic implication of the location and number of the metastatic mediastinal nodes...
Patients with stage IIIA-ipsilateral mediastinal lymph node involvement (N2) non–small cell lung can...
Objectives: This study compares early and late outcomes for treatment by video-assisted thoracic sur...
Background: The aim of this study was to analyse the outcome of surgically staged IIIA-N2 non-small-...
PurposeTo investigate prognoses of lung cancer patients prospectively enrolled in the Japan Lung Can...
OBJECTIVES: Treatment patterns and outcomes in a population-based database were examined to identify...
ObjectiveOptimal management of stage IIIA-N2 non–small cell lung cancer remains controversial. The s...
Background:The role of surgery in the treatment of non–small-cell lung cancer (NSCLC) with clinicall...
AbstractObjectivesNon–small cell lung cancer with mediastinal lymph node involvement is a heterogene...
Background: Surgery has been considered the most effective and standard treatment modality in non-sm...
OBJECTIVE: The surgical treatment of residual N2 disease following induction radio-chemotherapy (IT...
Objective: The role of surgery in patients with N2 non–small cell lung cancer is debated. The aim of...
ObjectiveThe aim of the present study was to identify the modern surgical results of pathologic T3 l...
To investigate the survival and prognostic factors in patients undergoing potentially curative resec...
Background:In the current TNM staging system revised in 1997 for lung cancer, intrapulmonary metasta...
To clarify the prognostic implication of the location and number of the metastatic mediastinal nodes...
Patients with stage IIIA-ipsilateral mediastinal lymph node involvement (N2) non–small cell lung can...
Objectives: This study compares early and late outcomes for treatment by video-assisted thoracic sur...
Background: The aim of this study was to analyse the outcome of surgically staged IIIA-N2 non-small-...
PurposeTo investigate prognoses of lung cancer patients prospectively enrolled in the Japan Lung Can...
OBJECTIVES: Treatment patterns and outcomes in a population-based database were examined to identify...
ObjectiveOptimal management of stage IIIA-N2 non–small cell lung cancer remains controversial. The s...